Publications

A phase 1/2, first-in-human, multicenter, open-label trial evaluating the safety, tolerability, and antileukemic activity of Debio1562M in patients with recurrent…

Debio 1562M, a 2nd Generation ADC Targeting CD37, Shows High Potency Against AML and MDS and Safe Toxicological Profile for…

CD37 is a Relevant Target for AML and MDS Treatment with Debio 1562M Antibody Drug Conjugate (ADC)

Debio 1562M, a next generation Antibody Drug Conjugate (ADC) targeting CD37 for AML and MDS treatment

The Multilink(TM) Linker is a promising approach to improve efficacy and safety of ADC’s